<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00905021</url>
  </required_header>
  <id_info>
    <org_study_id>H 24786 / EXTENT</org_study_id>
    <nct_id>NCT00905021</nct_id>
  </id_info>
  <brief_title>Exemestane With Sunitinib (SUTENT®) in Metastatic Breast Cancer</brief_title>
  <acronym>EXTENT</acronym>
  <official_title>EXTENT: Exemestane (AROMASIN®) in Combination With Sunitinib (SUTENT®) in Hormone Receptor Positive Metastatic Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Baylor Breast Care Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Baylor Breast Care Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators want to find out if the treatments used in this study are helpful to&#xD;
      patients that are diagnosed with hormone receptor positive metastatic breast cancer. The&#xD;
      investigators want to also look at any side effects that could happen while patients are on&#xD;
      the study treatments. The investigators want to see if there are any changes that could show&#xD;
      us if your cancer is responding to the study treatments.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study design is a phase II design. Eligible patients will undergo staging work up and&#xD;
      start treatment. Every 28-day period (4 weeks) will count as a cycle. Medical evaluations&#xD;
      will be performed every 4 weeks and staging work up will be repeated every 12 weeks.&#xD;
&#xD;
      The primary objective of the study is to assess progression free survival (PFS) of treatment&#xD;
      with exemestane and sunitinib in post¬menopausal subjects with hormone receptor positive&#xD;
      (ER-positive and/or PR-positive) unresectable locally advanced or metastatic breast cancer&#xD;
      subjects who have progressed on prior hormonal treatment.&#xD;
&#xD;
      In addition we want to:&#xD;
&#xD;
        1. Obtain assessments of overall response rate (ORR), clinical benefit rate (CBR), and&#xD;
           overall survival (OS).&#xD;
&#xD;
        2. Determine the safety and tolerability of the combination regimen.&#xD;
&#xD;
        3. Study molecular changes in tissue biopsies, circulating tumor cells (CTCs), and&#xD;
           circulating endothelial cells (CECs), and explore associations with treatment response&#xD;
           and resistance.&#xD;
&#xD;
      1. Blood samples will be drawn for enumeration and profiling of circulating tumor cells and&#xD;
      circulating endothelial cells at study entry (prior to starting study medications), four&#xD;
      weeks after starting study medications, twelve weeks after starting study medications and at&#xD;
      disease progression. These samples will be strongly encouraged but the patients may decline&#xD;
      any or all of them without impacting their eligibility or continuation on the study.&#xD;
&#xD;
      2. If the patient participating on the study has an easily accessible breast mass or&#xD;
      metastatic lesion (e.g. lymphadenopathy, skin metastasis, chest wall metastasis), a core&#xD;
      needle or punch biopsy will be obtained at study entry (prior to starting study medications),&#xD;
      four weeks after starting study medications, and at disease progression. These biopsies will&#xD;
      be strongly encouraged but the patients may decline any or all of them without impacting&#xD;
      their eligibility or continuation on the study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Sponsor withdrew support&#xD;
  </why_stopped>
  <start_date>March 2010</start_date>
  <completion_date type="Actual">February 2012</completion_date>
  <primary_completion_date type="Actual">January 2011</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to Disease Progression in Weeks</measure>
    <time_frame>Medical evaluation every 4 weeks;The study does not have a fixed time frame for each participant. Duration of therapy depends on individule response, evidence of disease progression and tolerance</time_frame>
    <description>Time from the first day of treatment to date of progression in weeks</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Obtain Assessments of Overall Response Rate, Clinical Benefit Rate, and Overall Survival</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine the Safety and Tolerability</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Study Molecular Changes in Tissue Biopsies, Circulating Tumor Cells, and Circulating Endothelial Cells</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">4</enrollment>
  <condition>Metastatic Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Exemestane plus Sutent</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All patients enrolled on the study will receive treatment as follows:&#xD;
Exemestane 25 mg by mouth every day.&#xD;
Sunitinib 37.5 mg by mouth every day.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Exemestane</intervention_name>
    <description>Exemestane 25 mg by mouth every day.</description>
    <arm_group_label>Exemestane plus Sutent</arm_group_label>
    <other_name>Aromasin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sutent</intervention_name>
    <description>Sunitinib 37.5 mg by mouth every day.</description>
    <arm_group_label>Exemestane plus Sutent</arm_group_label>
    <other_name>(Sunitinib)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Must have metastatic breast cancer or locally advanced not amenable to curative&#xD;
             therapy.&#xD;
&#xD;
          2. Measurable or evaluable disease are eligible.&#xD;
&#xD;
          3. Tumors must be Estrogen Receptor (ER)-positive and/or Progesterone Receptor&#xD;
             (PR)-positive.&#xD;
&#xD;
          4. Human Epidermal Growth Factor Recepter 2 (HER2)-positive tumors are allowed but must&#xD;
             have failed Herceptin therapy.&#xD;
&#xD;
          5. Postmenopausal&#xD;
&#xD;
          6. No more than 3 lines of chemotherapy&#xD;
&#xD;
          7. No more than 3 lines of hormonal therapy&#xD;
&#xD;
          8. Bisphosphonates may be given according to their product license&#xD;
&#xD;
          9. Left ventricular ejection fraction within institutional normal limits&#xD;
&#xD;
         10. Liver function and kidney function tests within the upper limit of normal. In patients&#xD;
             with liver metastasis, liver function tests should be &lt; 5 times the upper limit of&#xD;
             normal.&#xD;
&#xD;
         11. Adequate blood counts&#xD;
&#xD;
         12. Normal thyroid function tests.&#xD;
&#xD;
         13. Patients with Central Nervous System (CNS) metastatic disease are allowed if the&#xD;
             disease is stable for more than 3 months by CT or MRI.&#xD;
&#xD;
         14. Adequate general health (Eastern Cooperative Oncology Group (ECOG) performance status&#xD;
             0-2).&#xD;
&#xD;
         15. Able to give informed consent and follow the procedures of the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients previously treated with exemestane in any setting.&#xD;
&#xD;
          2. Patients previously treated with sunitinib.&#xD;
&#xD;
          3. Patients with cardiac dysfunction or active cardiac disease&#xD;
&#xD;
          4. Patients with uncontrolled CNS metastasis.&#xD;
&#xD;
          5. Poorly controlled hypertension&#xD;
&#xD;
          6. Blood counts or liver and kidney tests that fall outside the ranges outlined in&#xD;
             inclusion criteria 9-10 above.&#xD;
&#xD;
          7. ECOG performance status 3 or 4.&#xD;
&#xD;
          8. History of other malignancy within the last 5 years, except for carcinoma in situ of&#xD;
             the cervix or basal cell carcinoma of the skin.&#xD;
&#xD;
          9. History of a cerebrovascular accident, non-catheter related deep vein thrombosis, or&#xD;
             pulmonary embolism in the last 5 years.&#xD;
&#xD;
         10. Major surgical procedure or significant traumatic injury within 28 days prior to study&#xD;
             entry.&#xD;
&#xD;
         11. Premenopausal status.&#xD;
&#xD;
         12. History of receiving any investigational treatment within 28 days of study medication&#xD;
             initiation.&#xD;
&#xD;
         13. Current known infection.&#xD;
&#xD;
         14. Current severe, uncontrolled systemic disease (e.g., clinically significant&#xD;
             cardiovascular, pulmonary, or metabolic disease; wound healing disorders; ulcers; or&#xD;
             bone fractures).&#xD;
&#xD;
         15. Medical or psychiatric condition that in the opinion of the principal investigator&#xD;
             impair their ability to participate in the study.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mothaffar Rimiawi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Baylor College of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Baylor College of Medicine, Lester and Sue Smith Breast Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>May 18, 2009</study_first_submitted>
  <study_first_submitted_qc>May 19, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 20, 2009</study_first_posted>
  <results_first_submitted>February 6, 2012</results_first_submitted>
  <results_first_submitted_qc>April 27, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 28, 2012</results_first_posted>
  <last_update_submitted>July 9, 2020</last_update_submitted>
  <last_update_submitted_qc>July 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Baylor Breast Care Center</investigator_affiliation>
    <investigator_full_name>Mothaffar Rimawi</investigator_full_name>
    <investigator_title>Medical Director</investigator_title>
  </responsible_party>
  <keyword>Breast Cancer</keyword>
  <keyword>Metastatic</keyword>
  <keyword>Hormone Receptor Positive</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sunitinib</mesh_term>
    <mesh_term>Exemestane</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Exemestane Plus Sutent</title>
          <description>All patients enrolled on the study will receive treatment as follows:&#xD;
Exemestane 25 mg by mouth every day.&#xD;
Sunitinib 37.5 mg by mouth every day.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2">2 patients were off study due to AE.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Exemestane Plus Sutent</title>
          <description>All patients enrolled on the study will receive treatment as follows:&#xD;
Exemestane 25 mg by mouth every day.&#xD;
Sunitinib 37.5 mg by mouth every day.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="4"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Time to Disease Progression in Weeks</title>
        <description>Time from the first day of treatment to date of progression in weeks</description>
        <time_frame>Medical evaluation every 4 weeks;The study does not have a fixed time frame for each participant. Duration of therapy depends on individule response, evidence of disease progression and tolerance</time_frame>
        <population>2 patients developed disease progression.</population>
        <group_list>
          <group group_id="O1">
            <title>Exemestane Plus Sunitinib</title>
            <description>All patients enrolled on the study will receive treatment as follows:&#xD;
Exemestane 25 mg by mouth every day.&#xD;
Sunitinib 37.5 mg by mouth every day.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Disease Progression in Weeks</title>
          <description>Time from the first day of treatment to date of progression in weeks</description>
          <population>2 patients developed disease progression.</population>
          <units>week</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.1" lower_limit="10.9" upper_limit="11.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Obtain Assessments of Overall Response Rate, Clinical Benefit Rate, and Overall Survival</title>
        <time_frame>5 years</time_frame>
        <population>The study was terminated early before target accrual. 4 patients were enrolled and received treatment. 2 patients developed progression and 2 patients was drop-off the study due to adverse events.</population>
        <group_list>
          <group group_id="O1">
            <title>Exemestane Plus Sunitinib</title>
            <description>This is a single arm study. All patients received Exemestane 25mg per day and Sunitinib 37.5 mg per day.</description>
          </group>
        </group_list>
        <measure>
          <title>Obtain Assessments of Overall Response Rate, Clinical Benefit Rate, and Overall Survival</title>
          <population>The study was terminated early before target accrual. 4 patients were enrolled and received treatment. 2 patients developed progression and 2 patients was drop-off the study due to adverse events.</population>
          <units>paticipants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">The study was terminated early before target accrual and the secondary analyses were not conducted due to insufficient number of participants with events.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Determine the Safety and Tolerability</title>
        <time_frame>5 years</time_frame>
        <population>The study was terminated early before target accrual. 4 patients were enrolled and received treatment. 2 patients developed progression and 2 patients was drop-off the study due to adverse events.</population>
        <group_list>
          <group group_id="O1">
            <title>Exemestane Plus Sunitinib</title>
            <description>This is a single arm study. All patients received Exemestane 25mg per day and Sunitinib 37.5 mg per day.</description>
          </group>
        </group_list>
        <measure>
          <title>Determine the Safety and Tolerability</title>
          <population>The study was terminated early before target accrual. 4 patients were enrolled and received treatment. 2 patients developed progression and 2 patients was drop-off the study due to adverse events.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">The study was terminated early before target accrual and the secondary analyses were not conducted due to insufficient number of participants.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Study Molecular Changes in Tissue Biopsies, Circulating Tumor Cells, and Circulating Endothelial Cells</title>
        <time_frame>5 years</time_frame>
        <population>The study was terminated early before target accrual. 4 patients were enrolled and received treatment. 2 patients developed progression and 2 patients was drop-off the study due to adverse events.</population>
        <group_list>
          <group group_id="O1">
            <title>Exemestane Plus Sunitinib</title>
            <description>This is a single arm study. All patients received Exemestane 25mg per day and Sunitinib 37.5 mg per day.</description>
          </group>
        </group_list>
        <measure>
          <title>Study Molecular Changes in Tissue Biopsies, Circulating Tumor Cells, and Circulating Endothelial Cells</title>
          <population>The study was terminated early before target accrual. 4 patients were enrolled and received treatment. 2 patients developed progression and 2 patients was drop-off the study due to adverse events.</population>
          <units>cell</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="NA" upper_limit="NA">The study was terminated early before target accrual. No correlative study was performed.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Medical evaluation every 4 weeks. The study does not have a fixed time frame for each participant. Duration of therapy depends on individule response, evidence of disease progression and tolerance.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Exemestane Plus Sutent</title>
          <description>All patients enrolled on the study will receive treatment as follows:&#xD;
Exemestane 25 mg by mouth every day.&#xD;
Sunitinib 37.5 mg by mouth every day.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertriglyceridaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>leukopenia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Hemoglobin</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>platelets</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Thyroid function, low</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Ocular/Visual</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Mucositis/stomatitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>AST, SGOT(serum glutamic oxaloacetic transaminase)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Alkaline phosphatase</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatology/Skin</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Rash: acne/acneiform</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombosis/embolism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Mothaffar Rimawi</name_or_title>
      <organization>Baylor College of Medicine</organization>
      <phone>713-798-1311</phone>
      <email>rimawi@bcm.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

